The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417. Epub 2018 Jan 25.

Abstract

Background and objectives: The significance of persistent hematuria or proteinuria in patients with ANCA-associated vasculitis who are otherwise in clinical remission is unclear.

Design, setting, participants, & measurements: A post hoc analysis was conducted using participants enrolled in two randomized, placebo-controlled clinical trials who had active GN due to ANCA-associated vasculitis, had positive ANCA, and achieved remission by month 6. Dipstick and microscopic urinalyses were performed at each visit. Persistent hematuria or proteinuria for at least 6 months and the cumulative duration of hematuria were examined. Renal relapse was defined as new or worsening red blood cell casts and/or worsening kidney function according to the Birmingham Vasculitis Activity Score for Granulomatosis with Polyangiitis.

Results: There were 149 patients included in this study: 42% had persistent hematuria, and 43% had persistent proteinuria beyond 6 months. Persistent hematuria was associated with a significantly higher risk of relapse, even after adjusting for potential confounders (subdistribution hazard ratio, 3.99; 95% confidence interval, 1.20 to 13.25; P=0.02); persistent proteinuria was not associated with renal relapse (subdistribution hazard ratio, 1.44; 95% confidence interval, 0.47 to 4.42; P=0.53). Furthermore, greater cumulative duration of hematuria was significantly associated with a higher risk of renal relapse (adjusted subdistribution hazard ratio, 1.08 per each month; 95% confidence interval, 1.03 to 1.12; P<0.01). The median time to renal relapse was 22 months.

Conclusions: In patients with ANCA-associated vasculitis and kidney involvement who achieve remission after induction therapy, the presence of persistent hematuria, but not proteinuria, is a significant predictor of future renal relapse.

Keywords: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; Erythrocytes; Granulomatosis with Polyangiitis; Humans; Recurrence; Urinalysis; glomerulonephritis; hematuria; proteinuria; relapse; vasculitis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / diagnosis
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / urine*
  • Biomarkers / urine
  • Disease Progression
  • Etanercept / therapeutic use
  • Female
  • Glomerulonephritis / diagnosis
  • Glomerulonephritis / drug therapy
  • Glomerulonephritis / immunology
  • Glomerulonephritis / urine*
  • Hematuria / diagnosis
  • Hematuria / drug therapy
  • Hematuria / immunology
  • Hematuria / urine*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / immunology
  • Kidney Failure, Chronic / urine
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Proteinuria / diagnosis
  • Proteinuria / drug therapy
  • Proteinuria / immunology
  • Proteinuria / urine*
  • Randomized Controlled Trials as Topic
  • Reagent Strips
  • Recurrence
  • Remission Induction
  • Risk Assessment
  • Risk Factors
  • Rituximab / therapeutic use
  • Time Factors
  • Treatment Outcome
  • Urinalysis* / instrumentation

Substances

  • Biomarkers
  • Immunosuppressive Agents
  • Reagent Strips
  • Rituximab
  • Etanercept